artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography

AI-CAD marked axillary lymph node and region in right upper outer quadrant (arrows and thin line outlining both sites) and assigned an abnormality score of 28%.


August 11, 2021 — According to an open-access Editor’s Choice article in the American Journal of Roentgenology (AJR), artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography.

“After BCT, adjunct digital breast tomosynthesis (DBT) or AI-CAD reduced recall rates and improved accuracy in the ipsilateral and contralateral breasts compared with digital mammography (DM),” wrote lead investigator Jung Hyun Yoon. “In the ipsilateral breast, addition of AI-CAD resulted in lower recall rate and higher accuracy than addition of DBT.”

Yoon and colleagues’ single-center retrospective study included 314 women (mean age, 53.2 years; 4 with bilateral breast cancer) who underwent BCT followed by DBT (mean interval from surgery to DBT, 15.2 months). Three breast radiologists independently reviewed images in three sessions: DM, DM with DBT, and DM with AI-CAD. Recall rates and diagnostic performance were compared between these three sessions using readers’ mean results.

Among these 314 women, the mean ipsilateral breast recall rate among all three readers was lower (p<.001) for DM with AI-CAD (1.9%) than for DM with DBT (4.1%). In the ipsilateral breast, both mean accuracy (97.0% vs 94.8%, p=.02) and specificity (98.3% vs 96.1%, p=.003) were higher for DM with AI-CAD than for DM with DBT, respectively.

Acknowledging that data regarding other AI-CAD applications for the post-BCT breast are scarce, “our study shows that recall rates decrease significantly when DBT or AI-CAD are used as adjuncts to DM for surveillance of the ipsilateral and contralateral breasts in women with a personal history of breast cancer after BCT,” the authors of this AJR article concluded.

For more information: www.arrs.org


Related Content

News | HIMSS

March 9, 2026 — Fujifilm Healthcare Americas Corp. is showcasing how its latest AI-powered enterprise imaging solutions ...

Time March 10, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
News | Ultrasound Imaging

Feb. 25, 2026 — GE HealthCare is introducing the next generation of LOGIQ general imaging ultrasound systems – an ...

Time February 25, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 19, 2026 — GE HealthCare recently announced 510(k) clearance of three new magnetic resonance (MR) innovations with ...

Time February 20, 2026
arrow
Subscribe Now